适合医疗保险人群的减重手术的比较有效性与安全性:系统综述
该系统综述纳入16项比较研究,评估65岁以上符合Medicare条件人群减重手术的有效性与安全性。与不手术或常规减重相比,手术减重更多,最长随访5.9年时总死亡率较低(HR 0.50,95%CI 0.31-0.79),但术后30天内死亡率高于非手术对照(1.55% vs 0.53%,P<.001)。RYGB较SG和AGB减重更多,但多数非减重结局相似,证据强度低至中等。
要点
- 减重手术较非手术减重更多,最长随访5.9年总死亡率较低(HR 0.50,95%CI 0.31-0.79)。
- 术后30天内死亡率高于非手术对照(1.55% vs 0.53%,P<.001)。
- RYGB较SG和AGB减重更多(4年时%EWL差23.8%,95%CI 16.2%-31.4%)。
核心结论
- 在Medicare人群中,减重手术作为减重治疗改善非减重结局的证据强度为低至中等。
- 需要设计良好的比较研究来可靠确定该人群减重手术的治疗效果。
研究设计与样本
- 系统综述,遵循PRISMA指南,检索2000年1月1日至2017年6月31日多个数据库及注册平台。
- 由6名研究者提取数据,因临床异质性未进行计划的meta分析,采用定性综合。
主要发现
- 与不手术或常规减重治疗相比,减重手术减重更多。
- 最长随访5.9年的研究中,减重术后总死亡率较低(HR 0.50,95%CI 0.31-0.79)。
- 基于1项研究,术后30天内死亡率高于非手术对照(1.55% vs 0.53%,P<.001)。
- 减重手术与较低心血管疾病风险相关(最大研究比较中HR 0.59,95%CI 0.44-0.79)。
- 减重手术与呼吸、肌肉骨骼、代谢和肾脏结局改善相关(eGFR增加9.84,95%CI 8.05-11.62 mL/min/1.73m2)。
关键数值与推荐
- RYGB较SG和AGB减重更多(最长随访4年时%EWL差23.8%,95%CI 16.2%-31.4%)。
- RYGB、SG和AGB三种术式与大多数非减重结局的关联相似。
- RYGB与SG总体术后并发症无统计学显著差异,但主要和/或严重并发症在RYGB后更常见。
- 上述关联至少存在中等程度的混杂、选择或测量偏倚风险。
临床怎么用
- 在Medicare eligible人群中,减重手术可改善非减重结局,但需权衡术后30天内死亡率较高的风险。
- 选择术式时,RYGB减重更多但严重并发症更常见,SG和AGB非减重结局相似。
- 证据强度低至中等,临床决策应结合个体风险评估和共享决策。
局限性
- 因临床异质性未进行meta分析,仅定性综合。
- 纳入研究存在至少中等程度的混杂、选择或测量偏倚风险。
- 证据强度低至中等,需要设计良好的比较研究确认治疗效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The prevalence of obesity in patients older than 65 years is increasing. A substantial number of beneficiaries covered by Medicare meet eligibility criteria for bariatric procedures. OBJECTIVE: To assess the comparative effectiveness and safety of bariatric procedures in the Medicare-eligible population. EVIDENCE REVIEW: This systematic review was conducted according to the PRISMA guidelines. Articles were identified through searches of PubMed, Embase, CINAHL, PsycINFO, Cochrane Central Trials Registry, Cochrane Database of Systematic Reviews, and scientific information packages from manufacturers, ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform, and US Food and Drug Administration drugs and devices portals from January 1, 2000, to June 31, 2017. Randomized and nonrandomized comparative studies that evaluated bariatric procedures in the Medicare-eligible population were eligible. Six researchers extracted data on design, interventions, outcomes, and study quality. Findings were synthesized qualitatively; a planned meta-analysis was not undertaken owing to clinical heterogeneity. FINDINGS: A total of 11 455 citations were screened for eligibility. Of those, 16 met the eligibility criteria. Compared with no surgery or conventional weight-loss treatment, bariatric surgery results in greater weight loss. Overall mortality after 30 days is lower among bariatric patients (hazard ratio, HR, 0.50; 95% CI, 0.31-0.79, in the study with the longest follow-up of 5.9 years), although, based on 1 study, mortality within 30 days of surgery was higher than in nonsurgically treated controls (1.55% vs 0.53%; P < .001). Bariatric surgery is associated with lower risk of cardiovascular disease (HR, 0.59; 95% CI, 0.44-0.79 in the largest study comparison) and with improvements in respiratory, musculoskeletal, metabolic, and renal outcomes (increase in estimated glomerular filtration rate, 9.84; 95% CI, 8.05-11.62 mL/min/1.73m2). Compared with sleeve gastrectomy (SG) and adjustable gastric banding (AGB), Roux-en-Y gastric bypass (RYGB) appears to be associated with greater weight loss (percent excess weight loss, 23.8% [95% CI, 16.2%-31.4%] at the longest follow-up of 4 years) but the 3 procedures have similar associations with most non-weight loss outcomes. Overall postoperative complications are not statistically significantly different between RYGB and SG, although major and/or serious complications are more common after RYGB. However, these associations are susceptible to at least moderate risk of confounding, selection, or measurement biases. CONCLUSIONS AND RELEVANCE: In the Medicare population, there is low to moderate strength of evidence that bariatric surgery as a weight loss treatment improves non-weight loss outcomes. Well-designed comparative studies are needed to credibly determine the treatment effects for bariatric procedures in this patient population.
引用
- Panagiotou OA, Markozannes G, Adam GP, et al. Comparative Effectiveness and Safety of Bariatric Procedures in Medicare-Eligible Patients: A Systematic Review. JAMA Surg. 2018. PMID: 30193303. doi:10.1001/jamasurg.2018.3326
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。